Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;183(1):133-136.
doi: 10.1111/bjh.14907. Epub 2017 Sep 14.

Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions

Swapna Thota  1   2 , Bhumika J Patel  1   2 , Meena Sadaps  1 , Suresh Balasubramanian  1 , Srinivasa Sanikommu  1 , Cassandra Hirsch  1 , Serena Marotta  3 , Mikkael A Sekeres  2 , Antonio M Risitano  3 , Jaroslaw P Maciejewski  1
Affiliations

Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions

Swapna Thota et al. Br J Haematol. 2018 Oct.
No abstract available

Keywords: T- LGL; alemtuzumab; aplastic anaemia; bone marrow failure; pure red cell aplasia.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statements

The authors declare no conflict of interest and no competing financial interests.

Figures

Fig 1.
Fig 1.
Response duration and treatment details of acquired bone marrow failure patients in the retrospective cohort.
See this image and copyright information in PMC

References

    1. Cerchione C, Catalano L, Cerciello G, Avilia S, Picardi M, Risitano AM, Pisano I, Alfinito F. & Pane F. (2015) Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA). Annals of Hematology, 94, 531–534. - PubMed
    1. Dumitriu B, Ito S, Feng X, Stephens N, Yunce M, Kajigaya S, Melenhorst JJ, Rios O, Scheinberg P, Chinian F, Keyvanfar K, Battiwalla M, Wu CO, Maric I, Xi L, Raffeld M, Muranski P, Townsley DM, Young NS, Barrett AJ & Scheinberg P. (2016) Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. The Lancet Haematology, 3, e22–e29. - PMC - PubMed
    1. Gomez-Almaguer D, Jaime-Perez JC, Garza-Rodriguez V, Chapa-Rodriguez A, Tarin-Arzaga L, Herrera-Garza JL, Ruiz-Arguelles GJ, Lopez-Otero A, Gonzalez-Llano O. & Rodriguez-Romo L. (2010) Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Annals of Hematology, 89, 299–303. - PubMed
    1. Kim H, Min YJ, Baek JH, Shin SJ, Lee EH, Noh EK, Kim MY & Park JH (2009) A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leukemia Research, 33, 222–231. - PubMed
    1. Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski MW, Lichtin AE & Maciejewski JP (2009) Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica, 94, 1407–1414. - PMC - PubMed

MeSH terms